Evidence map›Paper›PMID 42789071›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026

Acute toxicity and patient-reported quality of life during daily online adaptive radiotherapy versus conventional IGRT for localized prostate cancer: a prospective parallel cohort study.

Goda Kalinauskaite, Luise A Künzel, Kerstin Rubarth, Jakob Dannehl, Celina Höhne, Marcus Beck, Arne Grün, Julia Bauer, Thomas Wiegel, Reinhard Thamm and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Goda KalinauskaiteDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany. goda.kalinauskaite@charite.de.ORCID http://orcid.org/0000-0003-3798-1546
Luise A KünzelDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Kerstin RubarthDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Jakob DannehlDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Celina HöhneDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Marcus BeckDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Arne GrünDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Julia BauerDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Thomas WiegelClinic for Radiotherapy and Radiooncology, Ulm University Hospital, Albert-Einstein-Allee 23, 89081, Ulm, Germany.
Reinhard ThammClinic for Radiotherapy and Radiooncology, Ulm University Hospital, Albert-Einstein-Allee 23, 89081, Ulm, Germany.
Daniel ZipsDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Carolin SengerDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to prospectively compare clinician-reported acute toxicity and patient-reported health-related quality of life (HRQoL) between daily cone-beam CT (CBCT)-based online adaptive radiotherapy (oART) and image-guided radiotherapy (IGRT) in patients with localized prostate cancer treated with moderate hypofractionation. MATERIALS AND

methodsIn this prospective study, 74 patients with localized prostate cancer received either CBCT-based oART (n = 43) or CBCT-based IGRT (n = 31) with 62/57.6/48 Gy in 20 fractions, allocated pragmatically by convenience. Acute gastrointestinal (GI) and genitourinary (GU) toxicity was assessed weekly using CTCAE v5.0, and HRQoL was evaluated using the EORTC QLQ-C30 questionnaire at baseline and the end of therapy. Between-group differences were tested using Boschloo's exact test, Wilcoxon rank-sum test and t-tests; temporal and between-group changes were evaluated based on minimally clinically important differences (MCIDs).

resultsBaseline patient and treatment characteristics were similar, except for more high-/very high-risk tumors in the oART group (40.5% vs. 9.7%; p = 0.03). Online ART was associated with more favorable gastrointestinal toxicity, reflected by lower maximum toxicity grades (p = 0.028). Maximum genitourinary toxicity was comparable between groups (p = 0.793). More IGRT patients exceeded MCID thresholds for fatigue (74% vs. 37%; p = 0.004), physical functioning (27% vs. 3%; p = 0.009), and role functioning (48.1% vs. 22.9%; p = 0.04). Differences for global health, pain, social function, and diarrhea were not statistically significant but consistently favored oART.

conclusionDaily CBCT-based oART and IGRT were both well tolerated, with low rates of high-grade acute toxicity. In this exploratory analysis, oART was associated with a more favorable GI toxicity profile and better preservation of HRQoL. These hypothesis-generating findings suggest that adaptive workflows may provide measurable patient-centered benefits during prostate radiotherapy and warrant confirmation in larger prospective studies.

Indexed as

AI-assisted segmentationCone-beam computed tomographyCTCAEEORTC QLQ-C30Gastrointestinal ToxicityHealth-related quality of life

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.